摘要
本文观察了转输细胞因子(rTNF或rIL-2)激活的巨噬细胞对L615小鼠白血病的免疫治疗作用。结果显示转输rIL-2或rTNF激活的小鼠腹腔渗出性巨噬细胞可明显延长小鼠的平均存活期,并可使20％的晚期病鼠治愈。但单独转输巨噬细胞和注射rIL-2或rTNF,并结合化疗仅可诞长存活期,而不能使病鼠治愈,体外实验中观察到rIL-2或rTNF均有直接加强巨噬细胞杀瘤活性的功能。本文提示巨噬细胞的转输与细胞因子联合应用是继承性免疫治疗肿瘤中又一新的、有潜力的方法。
Immunotherapeutic effects of transferring murine peritoneal elicited macrophage against mouse leukemia(L615) were investigated.The results showed that in ACIT experiment cyclophosphamide chemotherapy and transferring macrophage (1 × 106/mouse) combined withrIL-2(2U/mouse) or rTNF (103U/mouse)5 days after L615 inoculation could prolong the mean survival time (MST> (P<0.01)and cure 20% of the advanced L615 leukemic mice. Transferring macrophage alone as well as injecting rIL-2 or TNF both combined with cyclophosphamide could prolong the MST(p<0.01) but cured no one. In vitro, we found that both rIL-2 and rTNF could augment the tumoricidal activity of macrophage against L615 and other tumor cell linecellsThese results indicated that transferring macrophage combined with cytokinea could be a new adoptive immundtherapy protocol for advanced cancer.
出处
《上海免疫学杂志》
CSCD
北大核心
1991年第5期264-267,共4页
Shanghai Journal of Immunology
基金
辽宁省教委青年科学基金
